Gold prices dip as December rate cut bets wane; economic data in focus
DUBLIN - Tudor Investment Corporation has disclosed a 3.06% stake in Avadel Pharmaceuticals Plc, according to a regulatory filing released Monday.
The investment firm reported owning and controlling 2,981,375 ordinary shares representing approximately 3.06% of Avadel, as well as additional interests through derivatives bringing their total position to 3.06%. The disclosure also revealed short positions of approximately 1.34% in the pharmaceutical company.
The filing, made under Rule 8.3 of the Irish Takeover Panel Act, shows that Tudor made several small purchases of Avadel shares on November 7, acquiring a total of 214 shares at prices ranging from $18.69 to $18.77 per share.
The disclosure includes details of Tudor’s options positions, including put options on 1,290,000 shares with an exercise price of $5 expiring in January 2026, as well as various other put and call options with different strike prices and expiration dates.
Such disclosures are required under Irish takeover rules when an entity holds interests in relevant securities representing 1% or more of a company that may be involved in a potential takeover situation.
The filing was submitted to the Irish Takeover Panel on November 10, 2025, as an opening position disclosure. Tudor indicated it is not making disclosures regarding any other party to a potential offer.
The information was provided in a regulatory news service filing based on a company press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.